Bio-Rad Laboratories, Inc. Class A Common Stock vs GraniteShares 2x Long COIN Daily ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B), while GraniteShares 2x Long COIN Daily ETF trades at $4.21. The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, GraniteShares 2x Long COIN Daily ETF nearer its low. Which is the better fit depends on your goals.
| BIO | CONL | |
|---|---|---|
Market Cap | $9.43B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $356.25 | $48.70 |
52-Week Low | $241.71 | $3.93 |
Enterprise Value | $9.18B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
CONL (GraniteShares 2x Long COIN Daily ETF) trades at $4.38, up 11.45% in the past 24 hours but remains significantly below year-to-date levels with a 67% decline. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. The ETF tracks Coinbase stock with 2x daily leverage, exposing investors to amplified volatility from cryptocurrency market movements.
The outlook remains challenging due to the volatility decay inherent in daily-reset leveraged products. While recent cryptocurrency strength provides potential upside, the structural design of CONL creates significant long-term erosion risk. Investors should understand the product's mechanics before considering positions in this high-risk instrument.
Trailing returns across standard periods
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.
Read more on CONL →